Chlamydia Market Report 2026

Chlamydia Market Overview

• Chlamydia market size has reached to $3.23 billion in 2025 • Expected to grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Impact Of Rising Sexually Transmitted Diseases On The Growth Of The Market • Market Trend: Advancements In Rapid Molecular Point-Of-Care Testing For Chlamydia Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chlamydia Market?

Chlamydia is a common sexually transmitted infection (STI) caused by Chlamydia trachomatis, often asymptomatic but potentially leading to complications like infertility and pelvic inflammatory disease. It is easily treatable with antibiotics, and prevention includes safe sex practices and regular STI screenings. The main types of tests for chlamydia include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, and others. Culture tests refer to the growing of bacteria from a sample in a laboratory to identify infections such as chlamydia. A healthcare provider takes a sample from the patient (usually from the cervix, urethra, or throat) and places it in a special culture medium. If chlamydia bacteria grow, it confirms the infection. These tests are reliable but can take longer than other methods. Drugs are administered through various routes, including oral, injectable, and others, and are used by various end-users, such as hospitals, diagnostic centers, ambulatory surgical centers, and others.

What Is The Chlamydia Market Growth Forecast?

The chlamydia market size is expected to see strong growth in the next few years. It will grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for point-of-care diagnostics, rising focus on preventive sexual healthcare, expansion of digital health screening platforms, growing investments in diagnostic innovation, increasing government-led sti control programs. Major trends in the forecast period include increasing adoption of rapid chlamydia testing methods, rising use of naat-based diagnostic techniques, growing focus on early sti screening programs, expansion of home-based testing solutions, enhanced awareness of asymptomatic infections.

Global Chlamydia Market Segmentation

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types 2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration 3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture 2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP) 3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection 4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot 5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

What Is The Driver Of The Chlamydia Market?

The increasing prevalence of sexually transmitted diseases is expected to propel the growth of the chlamydia market going forward. Sexually transmitted diseases (STDs) refer to infections that spread through sexual contact, including chlamydia, gonorrhea, and HIV. The rise in STDs is attributed to factors such as decreased condom use, lack of awareness, limited access to healthcare, and the prevalence of dating apps that facilitate multiple sexual partners. Chlamydia treatment helps reduce the spread of STDs by eliminating the infection, preventing complications, and lowering the risk of transmission to sexual partners. For instance, in October 2025, according to the Minority HIV/AIDS Fund (MHAF), an US-based government agency, an estimated in 2023, approximately 39.9 million individuals worldwide were living with HIV, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the increasing prevalence of sexually transmitted diseases is driving the growth of the chlamydia industry.

Key Players In The Global Chlamydia Market

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

Global Chlamydia Market Trends and Insights

Major companies operating in the chlamydia market are focusing on developing innovative solutions such as point-of-care molecular diagnostics expansion to enable faster, more accurate onsite detection and improve timely treatment outcomes. Point-of-care molecular diagnostics expansion refers to the broader adoption of rapid, onsite molecular tests that allow immediate detection of infections such as chlamydia without relying on centralized laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, received FDA 510(k) clearance along with a CLIA waiver for its cobas liat molecular tests, which are designed to diagnose sexually transmitted infections (STIs) at the point of care. These tests include multiplex assay panels that can detect and differentiate multiple STIs, such as chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample with results available in 20 minutes or less.

What Are Latest Mergers And Acquisitions In The Chlamydia Market?

In December 2023, Imaware, a US-based digital health company, acquired the consumer testing business of Binx Health for an undisclosed amount. With this acquisition, Imaware aims to strengthen its position as a leader in STI health screening, expand its consumer testing offerings, enhance access to at-home diagnostic solutions, and accelerate growth in the sexual health market. Binx Health is a US-based healthcare company that provides at-home testing solutions for sexually transmitted infections (STIs).

Regional Outlook

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chlamydia Market?

The chlamydia market includes revenues earned by entities by entities by providing services such as diagnostic testing services, screening programs, treatment services, telehealth and online consultations and related products such as lateral flow assays, enzyme-linked immunosorbent assay (Elisa) kits, multiplex STI panels, macrolides, and fluoroquinolones. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chlamydia Market Report 2026?

The chlamydia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.